Press Coverage
Hepatitis C Treatment: Study Finds No Liver, Kidney or Cardiovascular Adverse Effects
Interview mentions that an ISMP QuarterWatchTM report raising questions about whether direct acting antiviral medications for the treatment of Hepatitis C posed any significant safety risks for patients was the impetus for further study.
For the full text, visit MedicalResearch.com online.
More News
New solution helps organizations prepare frontline staff with essential safety knowledge
Respondents indicated MERP helped reduce risk, increase reporting, justify MSO positions
This article appeared on the Pharmacy Practice News website on April 12, 2023.